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INTRODUCTION 
Many potential drug candidates are characterized by a 
low oral bioavailability. Often, poor drug 
dissolution/solubility rather than limited permeation 
through the epithelia of the gastrointestinal tract are 
responsible for low oral bioavailability. The relationship 
between solution rate and absorption is particularly 
distinct when considering drugs of low solubility. 
Consequently, numerous attempts have been made to 
modify the dissolution characteristics of certain drugs in 
an effort to attain more rapid and more complete 
absorption. Among the techniques to increase aqueous 
solubility/dissolution rate, the formulation of solid 
dispersions is one of the most popular ones 1-2, although 
few marketed products rely on this concept. The interest 
in amorphous drug–polymer solid dispersions has grown 
due to the potential of improving bioavailability, 
particularly for poorly water-soluble drugs 3-7. The basis 
for this interest stems from the increased rate of 
dissolution, which can range from hundreds to thousands 
fold increase, even for the most insoluble active 
pharmaceutical ingredients 3. For drugs whose 
bioavailability is limited due to poor aqueous solubility 
(as in BSC class II drugs), the improvement in solubility 
may lead to enhanced bioavailability 8-11. Solid 
dispersion represents a useful pharmaceutical technique 
for increasing the dissolution, absorption, and therapeutic 
efficacy of drugs in dosage forms 12-13. The properties, 
performance, and practical applications of solid 
dispersions depend on factors such as: (a) the method of 
preparation, (b) composition, (c) selection of a suitable 
carrier, and (d) physicochemical properties of the drug 1, 
14. 
Modafinil is approved by the USFDA for the treatment 
of narcolepsy, hypersomnia, shift work sleep disorder 
and excessive daytime sleepiness associated with 
obstructive sleep apnoea and in adult it is used in 
attention deficient /hyperactivity disorder (ADHD) 15. It 
is rapidly absorbed after oral administration with peak 
plasma concentrations occurring at 2-4 hours. But the 
oral bioavailability the drug is very poor due to water 
insolubility 15. Modafinil is BCS class II drug; hence 
improvement of dissolution will lead to enhancement of 
bioavailability.  
In the present study, we prepared solid dispersions of 
modafinil using hydrophilic carriers 
(polyethyleneglycols) by two different methods i.e. 
melting method and solvent evaporation method, to 
improve its solubility. For purposes of comparison, 
physical mixtures were prepared by simple mixing and 
homogenization after pulverization of drug and carriers. 
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ABSTRACT 
Solid dispersions of modafinil were prepared using polyethyleneglycols, in various proportions by melting, solvent evaporation 
and kneading method. Based on the solubility, PEG6000 was selected and solid dispersion batch F6 containing drug:PEG6000 
in 1:3 ration was formulated as tablet (batch TF6) and evaluated for in-vitro drug dissolution and six month stability; and the 
results were compared with that of tablet containing physical mixture of drug:PEG6000 in 1:3 ratio (batch TF24) and 
convention tablet (batch CT) containing pure drug. Tablet batch TF24 had shown significant improvement of dissolution profile 
of modafinil when compared with that of tablet batch TF6 and CT. Present study conclusively demonstrated that PEG6000 
enhanced water solubility of modafinil by amorphisation, which was confirmed XRD and DSC; and also the melting method 
was found better than solvent evaporation.    
Key-words: solid dispersion, polyethyleneglycols, modafinil, solubility enhancement, in vitro dissolution, characterization. 
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MATERIALS 
Modafinil was obtained as a gift sample from alembic 
pharmaceuticals Ltd. (Vadodara, India); PEG4000, 
PEG6000, PEG8000, acetone and chloroform were 
purchased from S.D.Fine Chemicals Ltd. (Mumbai, 
India); hydrochloric acid was purchased from LobaChem 
(Mumbai, India). Distilled water was freshly prepared 
and used for the study. All the chemicals and reagents 
were of analytical reagent (AR) grade and used without 
further purifications. 
METHODS 
Preparation of solid dispersions 
Solid dispersions were prepared by three different 
methods i.e. melting method, solvent evaporation method 
and physical mixture. 
a) Melting method: Solid dispersions containing different 
weight ratios (1:1, 1:2, 1:3) of drug in PEG4000, 
PEG6000, and PEG8000 were prepared by melting the 
carriers in porcelain dish (at around 10 C more than the 
melting point of carriers on sand bath), dispersing the 
drug onto the molten carrier and cooling immediately on 
freezing mixture of ice and sodium chloride. The solid 
dispersions were then allowed to cool at an ambient 
temperature and stored in desiccators for 24 hours. The 
dry mass was scrapped, crushed and ground in a mortar 
and passed through sieve #40. The dried mass was stored 
in desiccator until further use.  
b) Solvent evaporation method: Solid dispersions 
containing different weight ratios (1:1, 1:2, 1:3) of drug 
in PEG4000, PEG6000, and PEG8000 were prepared by 
dissolving required amount of drug and carriers in 
solvent system containing acetone and chloroform in 1:1 
proportion. The solvent was evaporated at 40 C on 
water bath with continuous stirring and the resulting 
residues were dried under vacuum for 3 hours and stored 
in desiccators for overnight. The dry mass was ground in 
a mortar, passed through sieve #40 and stored in 
desiccator until further use.  
c) Kneading: Drug and carriers were blended in desired 
proportions using spatula for 10 minutes and then ground 
in mortar with pestle. The co-grinding mixture was then 
passed through sieve #40 and stored in desiccator until 
further use. 
Evaluation of solid dispersions 
a) Saturation solubility: The saturation solubility of 
drug, carriers and all the solid dispersions was 
determined by dispersing 1g of drug, carrier or solid 
dispersion into 100ml of distilled water contained in 
glass bottle and shaken for not less than 24 hours. 
Solubility was then determined in mg/ml using 
spectrophotometer with λmax at 222nm after filtration 
(through a 0.45μm Millipore filter) and necessary 
dilutions.  
b) Melting point: Melting point of drug, polymer and all 
the solid dispersions was determined using precision 
melting point apparatus. Two samples were tested at a 
time by placing a pinch of sample into the capillary and 
heating at slow and consistent rate. 
c) Stability: The prepared solid dispersions were stored 
in stability chamber at 45 + 2º C with 75% RH for 6 
months. The formulations were analysed for one point in 
vitro dissolution, solubility and melting point after 6 
months and compared with the results obtained with 
formulations prepared and analysed immediately. 
 
Characterisation of solid dispersions 
a) Differential Scanning Calorimetry (DSC) Analysis: 
DSC scans of the powdered samples were recorded using 
DSC- 822e Mettler Toledo with the Stare software. All 
the samples were weighed (4-5 mg) and heated for total 
time of 40 min at a scanning rate of 5° C/min under dry 
air (N2) flow (50 ml/min) at pressure of 25 psi between 
50 and 250° C (furnace temperature). Aluminium pans 
and lids (40μl capacity) were used for the study. 
b) X-ray diffraction analysis: X-ray diffraction (XRD) 
patterns were recorded on an X-diffractometer (Phillip 
PW 1130/00 diffractometer, Natherland), employing 
CuK∞ radiation source operating at 30 mA and 40 kV. 
Samples were scanned from 6 to 40° 2θ at a scanning 
rate of 0.02° 2θ s-1.  
Preparation of tablets 
Tablets containing either solid dispersions, drug-carrier 
physical mixture or simple drug equivalent to 100mg of 
modafinil were prepared by direct compression method 
after mixing with required amount of different 
ingredients as shown in table 4.  
Evaluation of tablets containing modafinil 
All the prepared tablets were subjected to routine quality 
control tests like hardness, friability and weight variation 
before evaluating for in vitro dissolution and stability 
study. 
In vitro dissolution study: In vitro dissolution study of 
modafinil was performed on 8 vessel USP type II 
dissolution test apparatus in 0.1N HCl with constant 
temperature 37+2° C and speed 50rpm. Aliquots were 
withdrawn at predetermined time intervals, analyzed by 
UV-visible spectrophotometric method and cumulative 
percentage release of drug was recorded.  
RESULTS  
Solid dispersions of Modafinil were prepared 
successfully by physical mixture and solvent evaporation 
method and compared with melting method of drug and 
carriers. All the prepared formulations were evaluated 
for saturation solubility and %CSE; and the data of 
composition and evaluations of all the formulations were 
recorded in Table 1, Table 2 and Table 3.  
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Table 1 Composition and evaluations of solid dispersions prepared by melting method 
Batch Drug PEG 
4000 
PEG 
6000 
PEG 8000 SS %CSE 
F1 100 100 - - 0.573 + 1.09 27.902 
F2 100 200 - - 1.103 + 1.12 73.103 
F3 100 300 - - 1.956 + 0.98 112.202 
F4 100 - 100 - 0.594 + 2.12 32.59 
F5 100 - 200 - 1.162 + 1.67 79.69 
F6 100 - 300 - 2.143 + 1.90 126.12 
F7 100 - - 100 0.564 + 1.43 25.96 
F8 100 - - 200 1.104 + 1.02 73.20 
F9 100 - - 300 2.036 + 0.78 118.14 
SS=Saturation solubility in mg/ml ;%CSE=cum. solubility enhancement 
Table 2 Composition and evaluations of solid dispersions prepared by solvent evaporation method 
Batch Drug PEG 4000 PEG 6000 PEG 8000 SS %CSE 
F10 100 100 - - 0.539 + 1.01 20.228 
F11 100 200 - - 1.037 + 1.21 65.717 
F12 100 300 - - 1.839 + 1.56 103.47 
F13 100 - 100 - 0.558 + 0.83 24.63 
F14 100 - 200 - 1.092 + 2.12 71.91 
F15 100 - 300 - 2.014 + 1.24 116.55 
F16 100 - - 100 0.519 + 1.37 15.91 
F17 100 - - 200 1.016 + 1.22 63.37 
F18 100 - - 300 1.873 + 1.01 106.06 
SS=Saturation solubility in mg/ml; %CSE=cum. Solubility enhancement 
Table 3 Composition and evaluations of physical mixtures 
Batch Drug PEG 4000 PEG 6000 PEG 8000 SS %CSE 
F19 100 100 - - 0.461 + 1.12 2.902 
F20 100 200 - - 0.529 + 1.23 9.089 
F21 100 300 - - 0.665 + 1.12 16.149 
F22 100 - 100 - 0.453 + 0.87 1.12 
F23 100 - 200 - 0.465 + 2.67 1.88 
F24 100 - 300 - 0.857 + 2.65 30.45 
F25 100 - - 100       0.451 + 1.78 0.61 
F26 100 - - 200 0.458 + 1.07 1.10 
F27 100 - - 300 0.844 + 1.35 29.49 
SS=Saturation solubility in mg/ml;%CSE=cum. Solubility enhancement 
Batch F24 was selected after comparing the saturation solubility, formulated in tablet dosage form and extensively 
evaluated for in vitro dissolution and stability study. Tablet containing batch F6 and pure drug were also prepared and 
evaluated to get better comparison of the data. 
All the three tablet batches were characterised for %CSE (Cumulative Solubility Enhancement), saturation solubility 
and in vitro drug dissolution, as recorded in table 5, to understand stability of the formulations. 
 
Table 4 Composition of tablet containing pure drug, solid dispersion and physical mixture 
Tablet ingredients Amount in mg 
Batch TF6 Batch TF24 Batch CT 
Drug* 500 500 100 
Cross povidone XL 28 28 28 
PVP K30 50 50 50 
Corn starch 15 15 15 
Flow Lac 100 80 85 90 
MCC 27 22 17 
Total  700 700 700 
*Solid dispersion and physical mixture are in proportion of drug:carrier 1:3, hence 500 mg of total formulation is 
equivalent to 100 mg of drug; batch TF6, TF24 and CT are coded for tablet of batch F9, batch F27 and convention 
tablet respectively. 
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Table 5 Data of stability study conducted for six months 
Batches %CSE       Saturation Solubility    % CDD 15 
0m 6m %d   0m 6m %d 0m 6m %d 
F24/TF24* 170.93 150.43 -11.99 3.511 2.173 -38.11 48.82 29.40 -39.78 
F6/TF6* 162.85 143.65 -11.78 1.229 1.143 -7.00 29.95 27.32 -8.78 
drug/CT* 140.56 131.56 -6.40 1.121 0.936 -16.50 32.89 27.01 -17.88 
% CDR 15= Cumulative percentage drug release after 15 minutes; % CSE and saturation solubility data is that of batch 
F6, F24 and pure drug; and %  CDR 15 data is of batch TF6, TF24 and CT.  
 
DISCUSSIONS 
By formulating solid dispersion of modafinil, the water 
solubility of pure drug was increased by 7 folds and 
melting point was reduced by 0 to 33 % in different 
batches, which suggested the conversion of crystalline 
form to amorphous form, which was then confirmed by, 
DSC (Fig. 1), XRD (Fig. 2) study. While comparing 
different carriers, PEG6000 was found to have higher 
potential to enhance the water solubility of modafinil by 
melting method. Hence, batch F24 showing maximum 
solubility enhancement was selected for extensive 
characterisation and compared with batch F6, as it is 
melting method of drug and PEG6000 in the same 
proportion. 
 
 
Fig. 1 DSC thermogram of A) pure drug, B) pure PEG 6000, C) batch F24 and D) batch F6 
 
 
Fig. 2 X-ray diffraction spectra of pure drug (A), PEG 6000 (B), solid dispersion of drug:PEG 6000 (C) at 1:3 ratio and 
physical mixture of drug:PEG 6000 (D) at 1:3 ratio 
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DSC thermogram of pure drug has shown very sharp 
melting endotherm at 166° C-171° C for melting and an 
exotherm at 174° C-190° C due to its decomposition. 
DSC thermogram of PEG 6000 has given a sharp 
endotherm at 59° C-62° C for melting. Solid dispersions 
batch F24 (drug:PEG6000 at 1:3 proportion by melting 
method) has given a sharp endotherm at 59° C-63° C that 
suggested that melting peak of drug was absent and 
melting point of the formulation was near to that of 
PEG6000. Hence the DSC study also suggested 
alteration in state of the drug which supported the 
amorphisation of drug that led to increase in solubility of 
the drug. 
It was observed in the XRD study that pure drug is 
crystalline in nature showing at least three intense peaks 
along with several small to intermediate peaks in the 
spectra and pure carrier PEG6000 is semi crystalline in 
nature showing two intense peaks in the spectra, but 
solid dispersion has no any intense peaks and showing 
only few peaks with lesser intensity as compared to pure 
drug and carrier. Hence this study confirmed that was 
converted in amorphous state in solid dispersion batch 
F24 which led to solubility enhancement. In spectra of 
melting method batch F6, reduction of number of peaks 
as well as intensity of peaks was observed which 
confirmed only partial conversion of crystalline form to 
amorphous form.   
In the present study, it was observed that as the 
proportion of hydrophilic carriers was increased, the 
solubility also increased which might be due to the 
improved wetting of drug particles by carrier as the 
particle surface rendered hydrophilic after coating by 
PEGs. Higher solubility enhancement was observed with 
PEG6000 than PEG8000 and PEG4000 due to some 
unknown cause but might be due to the similar melting 
behavior and crystalline properties which led to perfect 
solution of drug into carrier.  
 
  
Fig. 3 Comparative in vitro drug dissolution study performed initially and after six months 
Fig. 3 shows the in vitro dissolution profiles of modafinil 
from tablets containing solid dispersion and physical 
mixture of PEG6000 at 1:3 ratio; and conventional tablet. 
Modafinil is slightly soluble in water (16) which is 
reflected in the extent of drug dissolved after 15 minutes 
(32.89 %) from batch CT. Its hydrophobic property 
prevented the powder surface from contacting the 
dissolution medium. In contrast, the dissolution rate of 
modafinil from batch TF24 was significantly higher than 
that of batch TF6 and batch CT. The results indicated 
that TF24 exhibited 48.82 % drug dissolution in 15 
minutes as compared to only 29.95 % and 32.89 % from 
batch TF6 and batch CT respectively. The hydrophilic 
properties of PEG 6000 probably led to greater wetting 
and increased surface available for dissolution by 
reducing interfacial tension between the hydrophobic 
drug and the dissolution medium. 
All the three tablets (batch TF6, TF24 and CT) were also 
evaluated for stability study for the duration of six 
months, where results of melting point, saturation 
solubility and one point in vitro drug dissolution study 
(% cumulative drug released after 15 minutes) were 
compared. It was observed that, %CSE of solid 
dispersion (batch F24) was increase by 11.99 % as 
compared to 11.78 % and 6.40 % in melting method 
(batch F6) and conventional tablet (batch CT) 
respectively, suggested stability problem in solid 
dispersion. Similar results were obtained in saturation 
solubility study as well as in vitro dissolution study, 
where significant change in these properties was 
observed which indicated poor stability of solid 
dispersion or the amorphous form. Hence stabilization of 
solid dispersion was needed to make this formulation 
strategy successful. 
CONCLUSION 
Solid dispersions of modafinil prepared with different 
polyethylene glycols (PEG4000, PEG6000 and 
PEG8000) by melting and solvent evaporation method 
resulted in increased saturation solubility of drug. Based 
on saturation solubility study of different solid 
dispersion, batch F24 was selected, as it has shown better 
results, and formulated into tablet along with batch F6 
and pure drug; and evaluated for in vitro dissolution and 
stability study. As demonstrated by characterization of 
solid dispersion by DSC, XRD study, a decreased 
crystallinity of modafinil as well as the surface 
morphology of the polymeric particles can explain the 
enhanced solubility and improved dissolution rate. 
Tablets containing solid dispersion (batch TF24) had 
drug dissolution profiles that were better than those of 
batch TF6 and batch CT which explains that solid 
dispersion can be utilized successfully to enhance the 
water solubility of poorly water soluble drug.  
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